Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70121-1754-07 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-1755-07 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous April 15, 2022 In Use
70121-2453-01 70121-2453 Pemetrexed disodium PEMRYDI RTU 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 6, 2023 In Use
70121-2461-01 70121-2461 Pemetrexed disodium PEMRYDI RTU 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 6, 2023 In Use
70121-2462-01 70121-2462 Pemetrexed disodium PEMRYDI RTU 1000.0 mg/100mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 6, 2023 In Use
70121-2537-06 70121-2537 Leuprolide acetate Leuprolide acetate Hormonal Therapy GnRH Agonist Subcutaneous Nov. 7, 2022 In Use
70255-0010-02 70255-0010 BINIMETINIB MEKTOVI 15.0 mg/1 Chemotherapy MEK Inhibitor MEK 1/2 Oral June 27, 2018 In Use
70255-0010-03 70255-0010 BINIMETINIB MEKTOVI 15.0 mg/1 Chemotherapy MEK Inhibitor MEK 1/2 Oral June 27, 2018 In Use
70255-0020-01 70255-0020 Encorafenib BRAFTOVI 50.0 mg/1 Chemotherapy BRAF Inhibitor V600E Oral June 27, 2018 March 13, 2019 In Use

Found 10,000 results in 12 milliseconds — Export these results